Randal H Henderson
Overview
Explore the profile of Randal H Henderson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lukez A, Handorf E, Mendenhall N, Henderson R, Stish B, Davis B, et al.
Prostate
. 2023 Dec;
84(4):395-402.
PMID: 38108113
Background: We sought to characterize and compare late patient-reported outcomes (PROs) after moderately hypofractionated intensity modulated radiation therapy (IMRT) and proton beam therapy (PBT) for localized prostate cancer (PC). Methods:...
2.
Henderson R, Bryant C, Nichols Jr R, Mendenhall W, Mendenhall N
Prostate
. 2023 May;
83(11):1001-1010.
PMID: 37150849
Background: Locally recurrent prostate cancer following primary external beam radiotherapy without distant metastasis is a challenging problem, with no current consensus on the optimal management of these patients. Traditional whole-gland...
3.
Rutenberg M, Hoppe B, Starr J, Awad Z, Thomas M, Morris C, et al.
Int J Part Ther
. 2023 Feb;
9(3):18-29.
PMID: 36721483
Purpose: When treating esophageal cancer with radiation therapy, it is critical to limit the dose to surrounding structures, such as the lung and/or heart, as much as possible. Proton radiation...
4.
Mendenhall W, Brooks E, Smith S, Morris C, Bryant C, Henderson R, et al.
Int J Part Ther
. 2022 Feb;
8(3):36-42.
PMID: 35127974
Purpose: To determine factors that influence insurance approval for definitive proton therapy (PT) for prostate cancer. Materials And Methods: Between 2014 and 2018, 1592 insured patients with localized prostate cancer...
5.
Lockney N, Henderson R, Swarts S, Zhang Z, Zhang B, Li J, et al.
Int J Part Ther
. 2022 Feb;
8(3):28-35.
PMID: 35127973
Background: After radiation therapy (RT), circulating plasma cell-free DNA (cfDNA) released in response to RT damage to tissue can be measured within hours. We examined for a correlation between cfDNA...
6.
Butala A, Huang C, Bryant C, Henderson R, Hoppe B, Mendenhall N, et al.
Value Health
. 2022 Jan;
25(2):171-177.
PMID: 35094789
Objectives: Cost-effectiveness analyses (CEAs) may provide useful data to inform management decisions depending on the robustness of a model's input parameters. We sought to determine the level of heterogeneity in...
7.
Henderson R, Bryant C, Nichols R, Mendenhall W, Hoppe B, Su Z, et al.
Acta Oncol
. 2021 Dec;
61(4):468-477.
PMID: 34965846
Background: To report 5- and 7-year outcomes after image-guided moderately accelerated hypofractionated proton therapy (AHPT) for prostate cancer. Material And Methods: We reviewed the first 582 prostate cancer patients enrolled...
8.
Bryant C, Henderson R, Nichols R, Mendenhall W, Hoppe B, Vargas C, et al.
Int J Part Ther
. 2021 Nov;
8(2):1-16.
PMID: 34722807
Proton therapy is a promising but controversial treatment in the management of prostate cancer. Despite its dosimetric advantages when compared with photon radiation therapy, its increased cost to patients and...
9.
Kharod S, Mercado C, Morris C, Bryant C, Mendenhall N, Mendenhall W, et al.
Int J Part Ther
. 2021 Apr;
7(4):52-64.
PMID: 33829073
Purpose: Postprostatectomy radiation improves disease control, but limited data exist regarding outcomes, toxicities, and patient-reported quality of life with proton therapy. Method And Materials: The first 102 patients who were...
10.
Vapiwala N, Wong J, Handorf E, Paly J, Grewal A, Tendulkar R, et al.
Int J Radiat Oncol Biol Phys
. 2021 Feb;
110(4):1082-1089.
PMID: 33539968
Purpose: Data comparing moderately hypofractionated intensity modulated radiation therapy (IMRT) and proton beam therapy (PBT) are lacking. We aim to compare late toxicity profiles of patients with early-stage prostate cancer...